OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
OptimizeRx CorporationNASDAQ: OPRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $1.58M, compared with -$893K a year earlier. Trailing-twelve-month EBITDA was $18.9M.
Context
- EBITDA amounted to 15.1% of revenue in FY2025, up 5.5 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $26.23M (+58.3%) for the fiscal year ending Dec 2026, a slowdown from the +286.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.58M-83.9% QoQ
- Last fiscal yearDec 2025
- $16.57M+286.3% YoY
- LTMMar 2026
- $18.9M+423.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +276.4% | +4.7% | -271.6 pp |
| 1 year | +286.3% | +58.3% | -228.0 pp |
| 3-year CAGR | — | +20.9% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 16.57M USD
- Year-over-year change
- +286.3%
- 4-year CAGR
- +63.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.57M | +286.3% |
| FY2024 | 2024-12-31 | (8.9M) | +58.3% |
| FY2023 | 2023-12-31 | (21.31M) | -126.3% |
| FY2022 | 2022-12-31 | (9.42M) | -501.8% |
| FY2021 | 2021-12-31 | 2.34M | — |
EBITDA vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +423.3% is the highest of 10, against a peer median of -31.0%.
- EBITDA amounts to 17.6% of revenue for OPRX, versus a peer median of 20.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.57M USD | -26.5% | -3.8% | 9.4% | |
| LTM Mar 2026 | $27.87M USD | -32.4% | -15.0% | 20.1% | |
| LTM Mar 2026 | $22.22M USD | -11.4% | +75.9% | 16.3% | |
| LTM Mar 2026 | $18.9M USD | +423.3% | — | 17.6% | |
| LTM Feb 2026 | $17.31M USD | +4.6% | -7.7% | 21.5% | |
| LTM Mar 2026 | $11.6M USD | +101.6% | — | 4.9% | |
| LTM Mar 2026 | -CA$27.45M CAD | -716.2% | — | — | |
| LTM Mar 2026 | -$43.24M USD | -86.4% | — | 33.9% | |
| LTM Mar 2026 | -$66.08M USD | -31.0% | — | 81.4% | |
| LTM Mar 2026 | -$276.76M USD | -6900.5% | — | 7060.9% | |
| Peer median (excluding OPRX) | — | -31.0% | -5.8% | 20.8% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.29M | 62.45M | 71.52M | 92.13M | 109.43M |
| Cost of Revenue | 25.65M | 23.48M | 28.62M | 32.75M | 40.16M |
| Gross Profit | 35.64M | 38.97M | 42.9M | 59.38M | 69.27M |
| Gross Margin | 58.1% | 62.4% | 60.0% | 64.5% | 63.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 33.19M | 49.24M | 58.02M | 61.27M | 50.25M |
| Operating Expenses | 35.28M | 51.26M | 69.3M | 73.08M | 57.21M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| EBITDA | 2.34M | (9.42M) | (21.31M) | (8.9M) | 16.57M |
| EBITDA Margin | 3.8% | -15.1% | -29.8% | -9.7% | 15.1% |
| Operating Income | 361.1K | (12.29M) | (26.4M) | (13.71M) | 12.06M |
| Operating Margin | 0.6% | -19.7% | -36.9% | -14.9% | 11.0% |
| Interest Income | 16.98K | 852.3K | 2.19M | 329K | 353K |
| Interest Expense | 0 | 0 | 1.45M | 6.16M | 5.29M |
| Other Income / Expenses | 16.98K | 852.3K | 1.24M | (5.68M) | (5.11M) |
| Income Before Tax | 378.08K | (11.44M) | (25.16M) | (19.39M) | 6.95M |
| Pre-Tax Margin | 0.6% | -18.3% | -35.2% | -21.0% | 6.4% |
| Income Tax Expense | 0 | 0 | (7.6M) | 725K | 1.82M |
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Net Margin | 0.6% | -18.3% | -24.6% | -21.8% | 4.7% |
| EPS (Basic) | 0.02 | (0.64) | (1.03) | (1.10) | 0.28 |
| EPS (Diluted) | 0.02 | (0.64) | (1.03) | (1.10) | 0.27 |
| Weighted Avg Shares | 17.23M | 17.78M | 17.12M | 18.29M | 18.56M |
| Weighted Avg Shares (Diluted) | 17.69M | 17.78M | 17.12M | 18.29M | 19M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.